6533b82bfe1ef96bd128e10f
RESEARCH PRODUCT
Non-flavonoid polyphenols in osteoporosis: preclinical evidence
Gianluca GiavaresiCarla GentileViviana CostaAngela De LucaLavinia RaimondiFabio CaradonnaEufrosina DimarcoDaniele BellaviaValeria CarinaMilena Finisubject
Endocrinology Diabetes and MetabolismOsteoporosisFlavonoid030209 endocrinology & metabolismBioinformaticsBone resorption03 medical and health sciences0302 clinical medicineEndocrinologypolyphenolic compoundsSettore BIO/13 - Biologia ApplicataOsteogenesisSettore BIO/10 - Biochimicabone erosive diseasesHumansMedicineBone formationBone ResorptionProgressive osteopeniaFlavonoidschemistry.chemical_classificationepigeneticsbusiness.industryPolyphenolsfood and beveragesmedicine.diseaseSettore BIO/18 - GeneticachemistryPolyphenolosteoclastosteoblastOsteoporosisbusinessdescription
The development of progressive osteopenia and osteoporosis (OP) is due to the imbalance between bone resorption and bone formation, determining a lower bone resistance, major risks of fractures, with consequent pain and functional limitations. Flavonoids, a class of polyphenols, have been extensively studied for their therapeutic activities against bone resorption, but less attention has been given to a whole series of molecules belonging to the polyphenolic compounds. However, these classes have begun to be studied for the treatment of OP. In this systematic review, comprehensive information is provided on non-flavonoid polyphenolic compounds, and we highlight pathways implicated in the action of these molecules that act often epigenetically, and their possible use for OP treatment and prevention.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-07-01 | Trends in Endocrinology & Metabolism |